CN114984871B - Double-layer alginate microsphere for delivering probiotics and preparation method thereof - Google Patents
Double-layer alginate microsphere for delivering probiotics and preparation method thereof Download PDFInfo
- Publication number
- CN114984871B CN114984871B CN202210397992.0A CN202210397992A CN114984871B CN 114984871 B CN114984871 B CN 114984871B CN 202210397992 A CN202210397992 A CN 202210397992A CN 114984871 B CN114984871 B CN 114984871B
- Authority
- CN
- China
- Prior art keywords
- centrifuge tube
- sodium alginate
- aqueous solution
- solution
- calcium chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 51
- 239000006041 probiotic Substances 0.000 title claims abstract description 49
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 38
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 229940072056 alginate Drugs 0.000 title claims abstract description 18
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 18
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000000661 sodium alginate Substances 0.000 claims abstract description 56
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 56
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 56
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 28
- 229920000294 Resistant starch Polymers 0.000 claims description 34
- 235000021254 resistant starch Nutrition 0.000 claims description 34
- 239000007864 aqueous solution Substances 0.000 claims description 32
- 239000000499 gel Substances 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 24
- 239000001110 calcium chloride Substances 0.000 claims description 17
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 17
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 238000005119 centrifugation Methods 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 7
- 239000000017 hydrogel Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000008188 pellet Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 239000010802 sludge Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 abstract description 9
- 239000012530 fluid Substances 0.000 abstract description 2
- 230000035899 viability Effects 0.000 abstract description 2
- 239000010410 layer Substances 0.000 description 21
- 239000002245 particle Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 230000000529 probiotic effect Effects 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000973497 Siphonognathus argyrophanes Species 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- -1 gums Polymers 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于生物工程技术领域,具体涉及一种用于递送益生菌的双层海藻酸盐微球及其制备方法。本发明构建了一种用于递送益生菌的双层海藻酸盐微球体系,在离心力驱动流体流下,海藻酸钠和氯化钙溶液接触形成凝胶,合成尺寸可控制的双层微球(200‑500μm)。利用海藻酸钠将益生菌固定在微球内层,并在外层海藻酸钠溶液中添加RS3以减小凝胶的孔隙,提高了封装率和益生菌的生存活力。
The invention belongs to the technical field of bioengineering, and in particular relates to a double-layer alginate microsphere for delivering probiotics and a preparation method thereof. The present invention constructs a double-layer alginate microsphere system for delivering probiotics. Under centrifugal force driven fluid flow, sodium alginate and calcium chloride solution contact to form a gel, and the double-layer microsphere with controllable size is synthesized ( 200‑500 μm). Sodium alginate was used to immobilize probiotics on the inner layer of microspheres, and RS3 was added to the outer layer of sodium alginate solution to reduce the porosity of the gel, which improved the encapsulation rate and the viability of probiotics.
Description
技术领域:Technical field:
本发明属于生物工程技术领域,具体涉及一种用于递送益生菌的双层海藻酸盐微球及其制备方法。The invention belongs to the technical field of bioengineering, and in particular relates to a double-layer alginate microsphere for delivering probiotics and a preparation method thereof.
背景技术:Background technique:
益生菌是一类在人体内,对宿主有益的活性微生物,可有效预防肠胃炎、腹泻、肥胖等,但它容易受到胃酸、胆汁盐、pH等条件的影响。目前最常用的保护措施是微胶囊技术,以碳水化合物、植物胶、蛋白质等物质作为壁材,对其进行保护。但不同的壁材可能存在封装率低、保护效果不佳、成本高、安全性不足等问题,并且制备的微胶囊无法控制益生菌的分布,其中分布在表面的益生菌进入人体后会更快失活,而且,通过挤压法制备的微胶囊通常具有颗粒粒径大(2-5mm)、影响口感的问题。Probiotics are a type of active microorganisms that are beneficial to the host in the human body and can effectively prevent gastroenteritis, diarrhea, obesity, etc., but they are easily affected by conditions such as gastric acid, bile salts, and pH. At present, the most commonly used protective measure is microencapsulation technology, which uses carbohydrates, vegetable gums, proteins and other substances as wall materials to protect them. However, different wall materials may have problems such as low encapsulation rate, poor protection effect, high cost, and insufficient safety, and the prepared microcapsules cannot control the distribution of probiotics, and the probiotics distributed on the surface will enter the human body faster. Inactivation, and the microcapsules prepared by the extrusion method usually have the problem of large particle size (2-5mm), which affects the mouthfeel.
海藻酸钠是一种天然存在的多糖类物质,具有无毒、成本低等优点,其水溶液具有较高的黏度,与钙离子形成的水凝胶作为一种新型的多孔材料,常用作封装、递送益生菌的壁材,但其高孔隙率的性质可能会导致对益生菌封装率的降低以及更早的泄露。因此,通常与其他物质结合使用,提高稳定性和保护能力。Sodium alginate is a naturally occurring polysaccharide, which has the advantages of non-toxicity and low cost. Its aqueous solution has a high viscosity. The hydrogel formed with calcium ions is a new type of porous material, which is often used as a packaging material. , Wall material for delivering probiotics, but its high porosity may lead to lower encapsulation rate of probiotics and earlier leakage. Therefore, it is often used in combination with other substances to increase stability and protection.
淀粉是一种天然高分子碳水化合物,是人类为了维持生命和健康,必须摄取的食物。淀粉按其消化的速度和程度可分为快消化淀粉、慢消化淀粉和抗性淀粉,抗性淀粉(RS)是指不能被小肠消化吸收的淀粉,可进入结肠提供健康益处。其中的三型抗性淀粉(RS3)是一种老化淀粉,具有高度的稳定性,对于控制血糖浓度、体重等都有效,同时,它可作为益生元,进入大肠以后成为益生菌的营养源,代谢产物对人体也有益。Starch is a natural high-molecular carbohydrate, and it is a food that human beings must ingest in order to maintain life and health. Starch can be divided into fast-digesting starch, slow-digesting starch and resistant starch according to its speed and degree of digestion. Resistant starch (RS) refers to starch that cannot be digested and absorbed by the small intestine and can enter the colon to provide health benefits. Among them, type III resistant starch (RS3) is an aged starch with a high degree of stability, which is effective for controlling blood sugar concentration and body weight. Metabolites are also beneficial to the human body.
但现有技术中关于益生菌的递送体系研究还存在一些缺点和不足,例如,藻酸盐凝胶的孔隙率较高,导致海藻酸盐基微胶囊对益生菌的包封效率不高,仅有64.4%-79%;结冷胶-黄原胶和壳聚糖包被的海藻酸钠微球的结构比较柔软,结构稳定性有待改善[LinhPhuong Taa,Erika Bujnaa,Otilia Antal,et al.Effects of various polysaccharides(alginate,carrageenan,gums,chitosan)and their combination with prebioticsaccharides(resistant starch,lactosucrose,lactulose)on the encapsulationofprobiotic bacteria Lactobacillus casei 01strain[J].International Journal ofBiological Macromolecules,2021,183:1136-1144.];采用挤压法制成的微胶囊颗粒粒径通常较大,约为2-5mm,且形状不规则,对食品的品质、口感及其在食品中的流动性造成一定影响[田文静,朱莹丹,岳林芳,等.益生菌微胶囊化研究现状[J].中国食品学报,2016,16(8):186-194.]。。However, there are still some shortcomings and deficiencies in the research on the delivery system of probiotics in the prior art. For example, the porosity of alginate gel is relatively high, resulting in low encapsulation efficiency of alginate-based microcapsules for probiotics. There are 64.4%-79%; the structure of gellan gum-xanthan gum and chitosan-coated sodium alginate microspheres is relatively soft, and the structural stability needs to be improved [LinhPhuong Taa, Erika Bujnaa, Otilia Antal, et al.Effects of various polysaccharides (alginate, carrageenan, gums, chitosan) and their combination with prebiotics carbohydrates (resistant starch, lactosucrose, lactulose) on the encapsulation of probiotic bacteria Lactobacillus casei 01 strain [J]. International Journal of Biological Macromolecules, 202 1,183:1136-1144.] The particle size of the microcapsules made by the extrusion method is usually large, about 2-5mm, and the shape is irregular, which will have a certain impact on the quality, taste and fluidity of the food [Tian Wenjing, Zhu Yingdan, Yue Linfang, et al. Research status of probiotic microencapsulation [J]. Chinese Journal of Food Science, 2016, 16(8): 186-194.]. .
发明内容:Invention content:
为解决现有技术中关于益生菌的递送体系研究还存在的一些缺点和不足,本发明构建了一种用于递送益生菌的双层海藻酸盐微球体系,在离心力驱动流体流下,海藻酸钠和氯化钙溶液接触形成凝胶,合成尺寸可控制的双层微球(200-500μm)。利用海藻酸钠将益生菌固定在微球内层,并在海藻酸钠外层中添加RS3,以此减小凝胶微球表面的孔隙,提高了封装率和益生菌的生存活力。同时,微球外层的RS3作为益生元,有利于微球内层益生菌抵达大肠后的定植。In order to solve some shortcomings and deficiencies in the research on the delivery system of probiotics in the prior art, the present invention constructs a double-layer alginate microsphere system for delivering probiotics. Under the fluid flow driven by centrifugal force, alginate Sodium and calcium chloride solutions are contacted to form a gel, and double-layer microspheres (200-500 μm) with controllable size are synthesized. Sodium alginate was used to immobilize probiotics on the inner layer of microspheres, and RS3 was added to the outer layer of sodium alginate to reduce the pores on the surface of gel microspheres, improve the encapsulation rate and the viability of probiotics. At the same time, the RS3 on the outer layer of the microspheres acts as a prebiotic, which is conducive to the colonization of the probiotics in the inner layer of the microspheres after reaching the large intestine.
为达到上述目的,本发明通过以下技术方案实现,一种用于递送益生菌的双层海藻酸盐微球的制备方法,包括下列步骤:In order to achieve the above object, the present invention is achieved through the following technical solutions, a method for preparing double-layered alginate microspheres for delivering probiotics, comprising the following steps:
(1)配置海藻酸钠-益生菌混合液;其中,海藻酸钠的作用为将益生菌固定在微粒的内层。(1) Sodium alginate-probiotic mixed liquid is prepared; wherein, the role of sodium alginate is to fix the probiotics on the inner layer of the microparticles.
(2)配置海藻酸钠-抗性淀粉混合液;其中,海藻酸钠的作用为将抗性淀粉固定在微粒的外层;添加抗性淀粉可用来填充形成的海藻酸盐微球的孔隙,进而提高封装效率,并限制胆盐等向微球中的扩散,增强对益生菌的保护作用。抗性淀粉能进入海藻酸钠基质中,使微球具有更大的硬度和稳定性,并能更好的抵抗人体胃肠对其的消化作用。抗性淀粉具有在小肠中不被消化吸收的特点,可保护凝胶微球运送到特定的部位如结肠处再发挥作用。抗性淀粉可作为益生元,进入结肠以后成为益生菌的营养源,被结肠微生物群落用作发酵基质,代谢产物对人体也有益康益处。(2) configure the sodium alginate-resistant starch mixture; wherein, the role of sodium alginate is to fix the resistant starch on the outer layer of the particle; adding resistant starch can be used to fill the pores of the formed alginate microspheres, In turn, the encapsulation efficiency is improved, and the diffusion of bile salts and the like into the microspheres is limited, so as to enhance the protective effect on probiotics. Resistant starch can enter the sodium alginate matrix, making the microspheres have greater hardness and stability, and can better resist the digestion of the human gastrointestinal tract. Resistant starch has the characteristics of not being digested and absorbed in the small intestine, which can protect the gel microspheres to be transported to specific parts such as the colon and then play a role. Resistant starch can be used as a prebiotic. After entering the colon, it becomes a nutrient source for probiotics and is used as a fermentation substrate by the colonic microbial community. The metabolites are also beneficial to the human body.
(3)配置氯化钙水溶液;其中,氯化钙中的钙离子起到耦合作用,使海藻酸钠生成凝胶微粒。(3) Calcium chloride aqueous solution is configured; wherein, the calcium ions in the calcium chloride play a coupling role to make the sodium alginate generate gel particles.
(4)凝胶造粒:在离心力1000g条件下离心10min,使海藻酸钠-益生菌水溶液和海藻酸钠水溶液均速滴入氯化钙水溶液中,浸泡至水凝胶小球完全凝固后,分离出水凝胶小球。(4) Gel granulation: Centrifuge for 10 minutes under the condition of centrifugal force 1000g, drip sodium alginate-probiotic aqueous solution and sodium alginate aqueous solution into calcium chloride aqueous solution at an even speed, soak until the hydrogel pellets are completely solidified, The hydrogel pellets were isolated.
此时海藻酸钠羧基官能团的Na+与二价阳离子Ca2+发生离子交换反应。同时海藻酸钠的羧基官能团之间交联形成网络结构,从而形成凝胶微球。At this time, the Na + of the carboxyl functional group of sodium alginate undergoes an ion exchange reaction with the divalent cation Ca 2 + . At the same time, the carboxyl functional groups of sodium alginate are cross-linked to form a network structure, thereby forming gel microspheres.
离心力主要影响微球的大小和形状,离心力越大,颗粒越小。在离心力1000g条件下,能制备颗粒较小且形状均匀的凝胶微球。但当离心力大于1000g时,海藻酸钠微粒形成“尾巴”,导致颗粒形状不规则,会影响其加入食品后的感官。Centrifugal force mainly affects the size and shape of microspheres, the greater the centrifugal force, the smaller the particle. Under the condition of centrifugal force of 1000g, gel microspheres with smaller particles and uniform shape can be prepared. However, when the centrifugal force is greater than 1000g, the sodium alginate particles form a "tail", resulting in irregular particle shapes, which will affect the sensory perception after it is added to food.
进一步的,步骤(1)为配置质量浓度为1-3%(w/v)的海藻酸钠溶液;取已活化的益生菌菌液离心并弃去上清液,并将配置好的海藻酸钠溶液加入到菌泥中,涡旋直至均匀。Further, step (1) is to configure a sodium alginate solution with a mass concentration of 1-3% (w/v); take the activated probiotic bacteria liquid and centrifuge and discard the supernatant, and prepare the prepared alginate Add the sodium solution to the sludge and vortex until homogenous.
若海藻酸钠浓度过高,会导致海藻酸钠-益生菌混合液和海藻酸钠-抗性淀粉过于黏稠,无法在离心过程中将两个混合液滴入至氯化钙溶液,进而阻止凝胶微球的形成;若海藻酸钠浓度过低,会导致溶液过稀,离心过程中形成“线状”凝胶,无法形成凝胶微球。If the concentration of sodium alginate is too high, the sodium alginate-probiotic mixture and sodium alginate-resistant starch will be too viscous, and the two mixtures cannot be dripped into the calcium chloride solution during centrifugation to prevent coagulation. The formation of gel microspheres; if the concentration of sodium alginate is too low, the solution will be too dilute, and a "thread-like" gel will be formed during centrifugation, and gel microspheres will not be formed.
进一步的,步骤(2)为配置质量浓度为1-3%(w/v)的海藻酸钠溶液;取抗性淀粉水溶液离心并弃去上清液,并将配置好的海藻酸钠溶液加入到沉淀中,涡旋直至均匀;得到抗性淀粉的最终浓度为5-30mg/mL的溶液。Further, step (2) is to configure a sodium alginate solution with a mass concentration of 1-3% (w/v); centrifuge the resistant starch aqueous solution and discard the supernatant, and add the configured sodium alginate solution Into the pellet, vortex until homogeneous; resulting in a solution with a final concentration of resistant starch of 5-30 mg/mL.
对于海藻酸钠而言,选择该浓度范围可确保海藻酸钠与氯化钙可形成凝胶微球,并能将益生菌固定在内层,获得形状更规则的微球。若海藻酸钠浓度过高,会导致溶液过于黏稠,无法在离心过程中将海藻酸钠-益生菌混合液和海藻酸钠-抗性淀粉混合液滴入至氯化钙溶液,进而阻止凝胶微球的形成;若海藻酸钠浓度过低,会导致溶液过稀,离心过程中形成“线状”凝胶,无法形成凝胶微球。For sodium alginate, choosing this concentration range can ensure that sodium alginate and calcium chloride can form gel microspheres, and can fix probiotics in the inner layer to obtain microspheres with more regular shape. If the concentration of sodium alginate is too high, the solution will be too viscous to drop the sodium alginate-probiotic mixture and sodium alginate-resistant starch mixture into the calcium chloride solution during centrifugation, thereby preventing gelation Formation of microspheres; if the concentration of sodium alginate is too low, the solution will be too dilute, and a "thread-like" gel will form during centrifugation, preventing the formation of gel microspheres.
对于抗性淀粉而言,若抗淀粉浓度过高,会影响海藻酸钠-抗性淀粉水溶液的黏度,导致凝胶微球形状不规则,甚至出现仅生成单层微球的情况;若抗性淀粉浓度过低,无法充分地填补凝胶微球外层的孔隙,降低对包埋在凝胶微球内层益生菌的保护效果。For resistant starch, if the concentration of resistant starch is too high, the viscosity of sodium alginate-resistant starch aqueous solution will be affected, resulting in irregular shape of gel microspheres, or even a single layer of microspheres; if the resistance If the concentration of starch is too low, it cannot fully fill the pores of the outer layer of the gel microspheres, and reduce the protective effect on the probiotics embedded in the inner layer of the gel microspheres.
进一步的,步骤(1)和步骤(2)离心的参数为3000-5000rpm离心5-20min。Further, the centrifugation parameters of step (1) and step (2) are centrifugation at 3000-5000rpm for 5-20min.
离心参数选择该范围可确保离心完全,弃去上清后获得菌体和抗性淀粉,用于与海藻酸钠的混合溶液的配置。若离心转速和时间过低,会导致无法分离完全,上清液中仍含有较多的菌体和抗性淀粉。Selecting this range of centrifugation parameters can ensure that the centrifugation is complete. After discarding the supernatant, bacteria and resistant starch are obtained, which are used for the configuration of the mixed solution with sodium alginate. If the centrifugation speed and time are too low, the separation will not be complete, and the supernatant still contains more bacteria and resistant starch.
进一步的,步骤(3)为配置质量浓度为5-10%(w/v)的氯化钙溶液。Further, step (3) is to configure a calcium chloride solution with a mass concentration of 5-10% (w/v).
氯化钙浓度主要影响凝胶微球的形成和凝胶网络结构的紧密程度。此浓度范围适合于形状规则、结构紧密的双层凝胶微球的制备。The concentration of calcium chloride mainly affects the formation of gel microspheres and the tightness of gel network structure. This concentration range is suitable for the preparation of double-layer gel microspheres with regular shape and compact structure.
进一步的,步骤(4)采用离心模块完成;所述离心模块包括依次嵌套、由内向外的第一离心管、第二离心管和第三离心管;第一离心管内置贯穿底部的第一针头;第二离心管底部开口,连接第二针头;第三离心管管盖设有与第二离心管管口大小匹配的开口。Further, step (4) is completed using a centrifuge module; the centrifuge module includes a first centrifuge tube, a second centrifuge tube and a third centrifuge tube that are nested in sequence from inside to outside; the first centrifuge tube is built into the first centrifuge tube that runs through the bottom. The needle; the bottom opening of the second centrifuge tube is connected to the second needle; the cap of the third centrifuge tube is provided with an opening matching the size of the second centrifuge tube.
进一步的,第一离心管为0.5mL离心管,第二离心管为1.5mL离心管,第三离心管为50mL离心管。Further, the first centrifuge tube is a 0.5mL centrifuge tube, the second centrifuge tube is a 1.5mL centrifuge tube, and the third centrifuge tube is a 50mL centrifuge tube.
进一步的,利用上述装置凝胶造粒的步骤为:向0.5mL离心管中装入步骤(1)配置的海藻酸钠-益生菌水溶液,向1.5mL离心管中装入步骤(2)配置的海藻酸钠-抗性淀粉水溶液,向50mL离心管中装入步骤(3)配置的氯化钙水溶液,使针头距氯化钙溶液液面距离为0.45-1.35cm;然后进行离心。Further, the steps of using the above-mentioned device for gel granulation are as follows: load the sodium alginate-probiotic aqueous solution configured in step (1) into a 0.5mL centrifuge tube, and load the sodium alginate-probiotic aqueous solution configured in step (2) into a 1.5mL centrifuge tube. Sodium alginate-resistant starch aqueous solution, put the calcium chloride aqueous solution configured in step (3) into a 50mL centrifuge tube, so that the distance between the needle and the liquid surface of the calcium chloride solution is 0.45-1.35cm; then centrifuge.
一种利用上述方法制备的双层海藻酸盐微球,内层为将益生菌固定于其中的凝胶网络结构,外层为孔隙中填充着抗性淀粉的凝胶网络结构,尺寸为200-500μm,从而充分保护益生菌免受外界环境的伤害。A double-layer alginate microsphere prepared by the above method, the inner layer is a gel network structure in which probiotics are fixed, the outer layer is a gel network structure filled with resistant starch in the pores, and the size is 200- 500μm, so as to fully protect the probiotics from the damage of the external environment.
本发明的有益效果在于:The beneficial effects of the present invention are:
(1)在现有技术的基础上,本发明通过改良益生菌递送体系的制备工艺,制备出双层递送体系,能将益生菌很好地固定在微球内部一定区域,并在外层加入不被小肠消化吸收的抗性淀粉,提高了对益生菌的封装效率和保护能力,使其更多地到达结肠发挥健康益处。且所用原料都具有安全无毒、成本低的特点,可用于添加到食品中。(1) On the basis of the existing technology, the present invention prepares a double-layer delivery system by improving the preparation process of the probiotic delivery system, which can well fix the probiotics in a certain area inside the microsphere, and add different probiotics to the outer layer. The resistant starch digested and absorbed by the small intestine improves the encapsulation efficiency and protection ability of probiotics, allowing them to reach the colon more to exert health benefits. Moreover, the raw materials used are safe, non-toxic and low in cost, and can be added to food.
(2)本发明制备工艺简单、易控制、能耗低,且环境友好、成本低,能实现对益生菌活性的保护作用,且生成微球形状规则、粒径较小,对口感影响较小,适宜应用到食品中。(2) The preparation process of the present invention is simple, easy to control, low in energy consumption, environmentally friendly, low in cost, can realize the protective effect on the activity of probiotics, and the generated microspheres have regular shape and small particle size, and have little influence on the mouthfeel , suitable for application in food.
附图说明Description of drawings
图1是本发明的离心模块结构示意图。Fig. 1 is a schematic structural view of the centrifuge module of the present invention.
图2是双层海藻酸盐微球的结构图。Figure 2 is a structural diagram of a double-layer alginate microsphere.
图3是海藻酸钠浓度对微球形貌的影响。其中,左图:5%(左)、3%(右)海藻酸钠微球实物图;中图:5%海藻酸钠微球显微镜图;右图:3%海藻酸钠微球显微镜图Figure 3 is the effect of sodium alginate concentration on the morphology of microspheres. Among them, left picture: 5% (left), 3% (right) sodium alginate microspheres; middle picture: microscopic picture of 5% sodium alginate microspheres; right picture: microscopic picture of 3% sodium alginate microspheres
图4是离心力对海藻酸钠微球粒径的影响。Figure 4 is the effect of centrifugal force on the particle size of sodium alginate microspheres.
图中,第一离心管1、第二离心管2、第三离心管3、第一针头4、第二针头5。In the figure, a
具体实施方式:Detailed ways:
为使本发明实施例的目的、技术方案和优点更加清楚,下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention are clearly and completely described below. Obviously, the described embodiments are part of the embodiments of the present invention, not all Example. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts belong to the protection scope of the present invention.
实施例1:Example 1:
一种用于递送益生菌的双层海藻酸盐微球的制备方法,包括以下步骤:A preparation method for delivering probiotic double-layer alginate microspheres, comprising the following steps:
(1)分别称取海藻酸钠粉末,加入去离子水,配置成质量浓度为1-3%(w/v)的溶液,用装有桨式搅拌桨的直流搅拌机搅拌直至均匀;(1) Weigh the sodium alginate powder respectively, add deionized water, configure a solution with a mass concentration of 1-3% (w/v), and stir until uniform with a DC mixer equipped with a paddle-type stirring paddle;
取已活化的Enterococcus Faecium R7菌液于离心机中5000rpm离心10min,弃去上清液,并将配置好的2%(w/v)海藻酸钠溶液加入到菌泥中,涡旋直至均匀。Take the activated Enterococcus Faecium R7 bacteria solution and centrifuge at 5000rpm for 10 minutes in a centrifuge, discard the supernatant, and add the prepared 2% (w/v) sodium alginate solution to the bacteria sludge, and vortex until uniform.
(2)取抗性淀粉水溶液于离心机中5000rpm离心10min,弃去上清液,并将配置好的1%(w/v)海藻酸钠溶液加入到沉淀中,涡旋直至均匀。其中,抗性淀粉的最终浓度为5mg/mL。(2) Centrifuge the resistant starch aqueous solution at 5000 rpm for 10 minutes in a centrifuge, discard the supernatant, and add the prepared 1% (w/v) sodium alginate solution to the precipitate, and vortex until uniform. Wherein, the final concentration of resistant starch is 5 mg/mL.
(3)称取氯化钙粉末,加入去离子水,配置成质量浓度为10%(w/v)的氯化钙溶液。(3) Weigh the calcium chloride powder, add deionized water, and prepare a calcium chloride solution with a mass concentration of 10% (w/v).
(4)制备如图1的离心模块:离心模块包括依次嵌套、由内向外的第一离心管1、第二离心管2和第三离心管3;第一离心管内置贯穿底部的第一针头4;第二离心管底部开口,连接第二针头5;第一针头4针尾与第二针头5的针头相连通;第三离心管3管盖设有与第二离心管管口大小匹配的开口。将50mL的第三离心管的管盖剪出一定大小的空洞;将第二针头固定在1.5mL的第二离心管底部,离心管底部剪开小口;将第一针头插入0.5mL的第一离心管,并将两离心管嵌套组装,固定于50mL离心管盖上。(4) Prepare the centrifuge module as shown in Figure 1: the centrifuge module includes the
向0.5mL离心管中装入2%海藻酸钠-益生菌水溶液,向1.5mL离心管中装入1%海藻酸钠水溶液,向50mL离心管中装入10%氯化钙水溶液,使针头距氯化钙溶液液面保持一定距离。在离心力1000g条件下离心10min,使2%海藻酸钠-益生菌水溶液和1%海藻酸钠水溶液均速滴入10%氯化钙水溶液中,浸泡至水凝胶小球完全凝固后,分离出水凝胶小球,用去离子水冲洗后,保存于去离子水中。用光学显微镜观察其结构如图2所示。Put 2% sodium alginate-probiotic aqueous solution into a 0.5mL centrifuge tube, put 1% sodium alginate aqueous solution into a 1.5mL centrifuge tube, put 10% calcium chloride aqueous solution into a 50mL centrifuge tube, and keep the needle from The liquid level of calcium chloride solution is kept at a certain distance. Centrifuge at a centrifugal force of 1000g for 10 minutes, drop 2% sodium alginate-probiotic aqueous solution and 1% sodium alginate aqueous solution into 10% calcium chloride aqueous solution at an even speed, soak until the hydrogel beads are completely solidified, and separate the water Gel pellets were rinsed with deionized water and stored in deionized water. Its structure was observed with an optical microscope as shown in Figure 2.
使用血球计数板对离心后氯化钙溶液进行细胞计数,结果未发现有菌存在于离心后氯化钙溶液中,即表明双层海藻酸盐微球对菌的封装率可达100%。The cells of the calcium chloride solution after centrifugation were counted using a hemocytometer, and no bacteria were found in the calcium chloride solution after centrifugation, which indicated that the encapsulation rate of bacteria by double-layer alginate microspheres could reach 100%.
实施例2:Example 2:
分别配置下列三种溶液:Prepare the following three solutions respectively:
3%(w/v)海藻酸钠+益生菌水溶液;3% (w/v) sodium alginate + probiotic aqueous solution;
2%(w/v)海藻酸钠+20mg/mL抗性淀粉水溶液;2% (w/v) sodium alginate + 20mg/mL resistant starch aqueous solution;
8%(w/v)氯化钙水溶液。8% (w/v) calcium chloride in water.
其余均与实施例1相同。All the other are identical with
实施例3:Example 3:
分别配置下列三种溶液:Prepare the following three solutions respectively:
1%(w/v)海藻酸钠+益生菌水溶液;1% (w/v) sodium alginate + probiotic aqueous solution;
1%(w/v)海藻酸钠+5mg/mL抗性淀粉水溶液;1% (w/v) sodium alginate + 5mg/mL resistant starch aqueous solution;
5%(w/v)氯化钙水溶液。5% (w/v) calcium chloride in water.
其余均与实施例1相同。All the other are identical with
海藻酸钠浓度对微球形貌的影响如图3所示,氯化钙浓度、离心力均与实施例1相同。5%海藻酸钠制备的微球具有“尾巴”现象,这种不规则的球体结构加入食品后会影响口感,从而影响感官质量。降低海藻酸钠浓度使得溶液黏度减小,可明显改善该现象,浓度为3%时制备的微球为形状良好的球形。The influence of the concentration of sodium alginate on the morphology of the microspheres is shown in Figure 3, and the concentration of calcium chloride and the centrifugal force are the same as in Example 1. Microspheres prepared with 5% sodium alginate have a "tail" phenomenon, and this irregular sphere structure will affect the taste after being added to food, thereby affecting the sensory quality. Reducing the concentration of sodium alginate can reduce the viscosity of the solution, which can obviously improve this phenomenon. When the concentration is 3%, the prepared microspheres are spherical in good shape.
离心力对微球粒径的影响如图4所示,在海藻酸钠浓度、氯化钙浓度均与实施例1相同条件下,海藻酸钠微球的粒径随着离心力增大而减小。The effect of centrifugal force on the particle size of the microspheres is shown in Figure 4. Under the same conditions of sodium alginate concentration and calcium chloride concentration as in Example 1, the particle size of the sodium alginate microspheres decreases as the centrifugal force increases.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210397992.0A CN114984871B (en) | 2022-04-12 | 2022-04-12 | Double-layer alginate microsphere for delivering probiotics and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210397992.0A CN114984871B (en) | 2022-04-12 | 2022-04-12 | Double-layer alginate microsphere for delivering probiotics and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114984871A CN114984871A (en) | 2022-09-02 |
CN114984871B true CN114984871B (en) | 2023-05-30 |
Family
ID=83023731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210397992.0A Active CN114984871B (en) | 2022-04-12 | 2022-04-12 | Double-layer alginate microsphere for delivering probiotics and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114984871B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116570029A (en) * | 2023-03-13 | 2023-08-11 | 青岛农业大学 | Walnut oligopeptide probiotics microcapsule and preparation method thereof |
CN117297099B (en) * | 2023-11-07 | 2024-11-22 | 浙江大学 | Preparation method of probiotic coating based on sodium alginate and metal polyphenol network |
CN118525965A (en) * | 2024-04-16 | 2024-08-23 | 常州姿润诗生物科技有限公司 | Composite probiotics and preparation method thereof |
CN118857903A (en) * | 2024-09-25 | 2024-10-29 | 江苏凯基生物技术股份有限公司 | A method for embedding organoids |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6491102B2 (en) * | 2012-11-29 | 2019-03-27 | プロゲル プロプライアタリー リミティド | Microparticles containing probiotics, crosslinkable reagents, modified proteins, polyol plasticizers and trehalose |
CN104707575B (en) * | 2015-03-30 | 2017-05-03 | 西南科技大学 | Preparation method of magnetic core-shell alginate microsphere adsorbent |
CN109619593B (en) * | 2018-11-08 | 2022-06-10 | 淮阴工学院 | A kind of probiotic double-layer microcapsule and preparation method thereof |
CN109700781A (en) * | 2019-02-25 | 2019-05-03 | 绍兴同创生物科技有限公司 | A kind of probiotic microcapsule and preparation method thereof targeting enteron aisle |
CN112544978B (en) * | 2020-12-01 | 2023-10-03 | 上海扬彩生物科技有限公司 | Microcapsule-embedded probiotics capable of being released at fixed points in intestinal tracts and preparation method thereof |
-
2022
- 2022-04-12 CN CN202210397992.0A patent/CN114984871B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN114984871A (en) | 2022-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114984871B (en) | Double-layer alginate microsphere for delivering probiotics and preparation method thereof | |
CN110432496A (en) | Prebiotic ball of double-walled porous micro-capsule and preparation method thereof | |
CN108524455B (en) | Preparation method and application of calcium alginate/vaterite calcium carbonate composite microspheres with controllable pH-responsive release rate | |
CN114176227B (en) | Sodium alginate-coated layer-by-layer self-assembled probiotic microcapsule and preparation method thereof | |
CN101289648B (en) | Enterococcus faecium microcapsule formulation and method for preparing same | |
CN109700781A (en) | A kind of probiotic microcapsule and preparation method thereof targeting enteron aisle | |
CN103751791B (en) | The preparation method of the gel immobilized multilamellar capsule of a kind of chitosan composite Nano | |
CN107970227A (en) | A kind of preparation method of casein/sodium alginate composite microcapsule | |
CN109007807A (en) | A kind of microcapsules fruit ferment powder and preparation method thereof | |
CN107789332A (en) | A kind of calcium carbonate/calcium alginate composite microspheres with adjustable drug release rate based on two-phase biomineralization technology | |
CN110547468A (en) | Preparation method of probiotics microcapsule containing edible fungus oligosaccharide | |
CN106617094A (en) | Probiotic microcapsules and its preparation method and application | |
CN106617093A (en) | Acid-resistant, stable probiotic microcapsules, preparation method and application thereof | |
CN107375217A (en) | A kind of calcium carbonate (poly ornithine/fucosan)4Self assembly carrier and preparation method | |
CN104388416A (en) | Preparation method of microporous starch embedded lactic acid bacteria | |
CN105343883B (en) | The preparation method of the compound galapectite pipe microballoon of porous calcium carbonate | |
CN1241552C (en) | Konjaku gluocomannan-calcium alginate microball for carrying medicine and preparing method | |
CN112335884A (en) | Novel probiotic microsphere and preparation method thereof | |
CN116035212A (en) | Probiotic microcapsule with stress resistance and preparation method and application thereof | |
Wang et al. | Synergistic effects of pH and nano-calcium carbonate on sodium alginate gels and their application for encapsulation, protection, delivery and yoghurt of probiotics | |
CN1233320C (en) | Slow-releasing microball with nimoldipine and its preparing method | |
CN113230284A (en) | Synbiotic microencapsulated preparation based on multi-dimensional crosslinking and preparation method and application thereof | |
Koyama et al. | Evaluation of mass-transfer characteristics in alginate-membrane liquid-core capsules prepared using polyethylene glycol | |
CN117919194A (en) | Stable probiotic capsule and preparation method thereof | |
CN113812518B (en) | A kind of Salmonella phage microencapsulated microsphere and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |